CD8A and neoplasm: In vitro cell killing experiments showed that SRC‐1 deletion in CRC cells rendered tumor cells more sensitive to be killed by CD8+ T cells, which could be reversed by rescued expression of PD‐L1 in SRC‐1‐deficient CRC cells.